[
  {
    "symbol": "MRTX",
    "price": 37,
    "beta": 1.019366,
    "volAvg": 1028388,
    "mktCap": 2152915300,
    "lastDiv": 0,
    "range": "35.55-101.3",
    "changes": -0.3,
    "companyName": "Mirati Therapeutics, Inc.",
    "currency": "USD",
    "cik": "0001576263",
    "isin": "US60468T1051",
    "cusip": "60468T105",
    "exchange": "NASDAQ Global Select",
    "exchangeShortName": "NASDAQ",
    "industry": "Biotechnology",
    "website": "https://www.mirati.com",
    "description": "Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.",
    "ceo": "Mr. David D. Meek",
    "sector": "Healthcare",
    "country": "US",
    "fullTimeEmployees": "587",
    "phone": "858 332 3410",
    "address": "3545 Cray Court",
    "city": "San Diego",
    "state": "CA",
    "zip": "92121",
    "dcfDiff": 29.4119,
    "dcf": 82.5019,
    "image": "https://financialmodelingprep.com/image-stock/MRTX.png",
    "ipoDate": "2013-07-15",
    "defaultImage": false,
    "isEtf": false,
    "isActivelyTrading": true,
    "isAdr": false,
    "isFund": false
  }
]